Search Page

1

Cite

Share

The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.

Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. Obach RS, et al. Among authors: silber bm. J Pharmacol Exp Ther. 1997 Oct;283(1):46-58. J Pharmacol Exp Ther. 1997. PMID: 9336307

Cite

Share

2

Cite

Share

Optimization of Aryl Amides that Extend Survival in Prion-Infected Mice.

Giles K, Berry DB, Condello C, Dugger BN, Li Z, Oehler A, Bhardwaj S, Elepano M, Guan S, Silber BM, Olson SH, Prusiner SB. Giles K, et al. Among authors: silber bm. J Pharmacol Exp Ther. 2016 Sep;358(3):537-47. doi: 10.1124/jpet.116.235556. Epub 2016 Jun 17. J Pharmacol Exp Ther. 2016. PMID: 27317802 Free PMC article.

Cite

Share

3

Cite

Share

2-Aminothiazoles as therapeutic leads for prion diseases.

Gallardo-Godoy A, Gever J, Fife KL, Silber BM, Prusiner SB, Renslo AR. Gallardo-Godoy A, et al. Among authors: silber bm. J Med Chem. 2011 Feb 24;54(4):1010-21. doi: 10.1021/jm101250y. Epub 2011 Jan 19. J Med Chem. 2011. PMID: 21247166 Free PMC article.

Cite

Share

4

Cite

Share

Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice.

Silber BM, Rao S, Fife KL, Gallardo-Godoy A, Renslo AR, Dalvie DK, Giles K, Freyman Y, Elepano M, Gever JR, Li Z, Jacobson MP, Huang Y, Benet LZ, Prusiner SB. Silber BM, et al. Pharm Res. 2013 Apr;30(4):932-50. doi: 10.1007/s11095-012-0912-4. Epub 2013 Feb 16. Pharm Res. 2013. PMID: 23417511 Free PMC article.

Cite

Share

5

Cite

Share

2-Aminothiazoles with improved pharmacotherapeutic properties for treatment of prion disease.

Li Z, Silber BM, Rao S, Gever JR, Bryant C, Gallardo-Godoy A, Dolghih E, Widjaja K, Elepano M, Jacobson MP, Prusiner SB, Renslo AR. Li Z, et al. Among authors: silber bm. ChemMedChem. 2013 May;8(5):847-57. doi: 10.1002/cmdc.201300007. Epub 2013 Mar 18. ChemMedChem. 2013. PMID: 23509039 Free PMC article.

Cite

Share

6

Cite

Share

Driving drug discovery: the fundamental role of academic labs.

Silber BM. Silber BM. Sci Transl Med. 2010 May 5;2(30):30cm16. doi: 10.1126/scitranslmed.3000169. Sci Transl Med. 2010. PMID: 20445199

Cite

Share

7

Cite

Share

Pharmacokinetic profile of cefixime in man.

Faulkner RD, Yacobi A, Barone JS, Kaplan SA, Silber BM. Faulkner RD, et al. Among authors: silber bm. Pediatr Infect Dis J. 1987 Oct;6(10):963-70. doi: 10.1097/00006454-198710000-00035. Pediatr Infect Dis J. 1987. PMID: 3696837

Cite

Share

8

Cite

Share

Absolute bioavailability of cefixime in man.

Faulkner RD, Fernandez P, Lawrence G, Sia LL, Falkowski AJ, Weiss AI, Yacobi A, Silber BM. Faulkner RD, et al. Among authors: silber bm. J Clin Pharmacol. 1988 Aug;28(8):700-6. doi: 10.1002/j.1552-4604.1988.tb03203.x. J Clin Pharmacol. 1988. PMID: 3216036

Cite

Share

9

Cite

Share

Discovery and Preliminary SAR of Arylpiperazines as Novel, Brainpenetrant Antiprion Compounds.

Li Z, Gever J, Rao S, Widjaja K, Prusiner SB, Silber BM. Li Z, et al. Among authors: silber bm. ACS Med Chem Lett. 2013 Apr 11;4(4):397-401. doi: 10.1021/ml300472n. ACS Med Chem Lett. 2013. PMID: 23847718 Free PMC article.

Cite

Share

10

Cite

Share

Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells.

Silber BM, Gever JR, Li Z, Gallardo-Godoy A, Renslo AR, Widjaja K, Irwin JJ, Rao S, Jacobson MP, Ghaemmaghami S, Prusiner SB. Silber BM, et al. Bioorg Med Chem. 2013 Dec 15;21(24):7999-8012. doi: 10.1016/j.bmc.2013.09.022. Epub 2013 Sep 18. Bioorg Med Chem. 2013. PMID: 24183589 Free PMC article.

Cite

Share